Single Center First Year Experience and Outcomes with Impella 5.5 Left Ventricular Assist Device

Overview

Journal J Cardiothorac Surg

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2022 May 23

PMID 35606780

Authors

Joanna R Rock

Cynthia A Kos

Anthony Lemaire

Hirohisa Ikegami

Mark J Russo

Danyaal Moin

Kenneth Dulnuan

Deepa Iyer

Affiliations

Soon will be listed here.

Abstract

Background: The Impella 5.5® was approved by the FDA for use for mechanical circulatory support up to 14 days in late 2019 at limited centers in the United States. Our single center's experience with Impella 5.5® can expand the overall understanding for achieving successful patient outcomes as well as provide support for the expansion of its FDA-approved use.

Methods: This study is an IRB-approved single-center retrospective cohort analysis of hospitalized adult patient characteristics and outcomes in cases where the Impella 5.5® was utilized for mechanical circulatory support.

Results: A total of 26 implanted Impella 5.5® devices were identified in 24 hospitalized patients at our institution from January 2020 to January 2021. The overall survival rate during index hospitalization was 75%. Eleven Impella 5.5® devices were identified in 10 patients with an average device implantation greater than 14 days. Average device implantation for this subgroup was 27 days with a range of 15-80 days. Survival rate for Impella 5.5® use greater than 14 days was 67%. In the entire cohort and subgroup of device implantation > 14 days, evidence of end organ damage improved with Impella 5.5® use. Complications in our cohort and subgroup of device implantation > 14 days were similar to previously reported complication incidence of axillary inserted LVAD devices.

Conclusions: Our institution's experience with the Impella 5.5® has been strongly positive with favorable outcomes and helps to establish the Impella 5.5® as a viable option for mechanical circulatory support beyond 14 days.

Citing Articles

Are there etiology-specific risk factors for adverse outcomes in patients on Impella 5.5 support?.

Maigrot J, Thuita L, Tong M, Soltesz E, Smedira N, Unai S JTCVS Open. 2024; 21:123-137.

PMID: 39534347 PMC: 11551278. DOI: 10.1016/j.xjon.2024.04.014.

Association between Impella device support and elevated rates of gout flares: a retrospective propensity-matched study.

Sinclair De Frias J, Isha S, Olivero L, Raavi L, Narra S, Paghdar S BMC Rheumatol. 2024; 8(1):9.

PMID: 38424614 PMC: 10902952. DOI: 10.1186/s41927-024-00380-z.

Surgically implanted endovascular, microaxial left ventricular assist device: A single institution study.

Schumer E, Bai Y, Kotkar K, Masood M, Itoh A, Schilling J JTCVS Tech. 2024; 23:63-71.

PMID: 38351990 PMC: 10859563. DOI: 10.1016/j.xjtc.2023.10.012.

Placement of Temporary Left Ventricular Assist Device Using Monitored Anesthesia Care and Regional Anesthesia.

DePaolo J, Iyengar A, Cohen S, Kelly J, Spelde A, Wald J JACC Case Rep. 2023; 26():102067.

PMID: 38094172 PMC: 10715957. DOI: 10.1016/j.jaccas.2023.102067.

Cardiogenic shock etiology and exit strategy impact survival in patients with Impella 5.5.

Sicke M, Modi S, Hong Y, Bashline M, Klass W, Horn E Int J Artif Organs. 2023; 47(1):8-16.

PMID: 38053245 PMC: 10824236. DOI: 10.1177/03913988231214180.

References

Goldberg R, Makam R, Yarzebski J, McManus D, Lessard D, Gore J . Decade-Long Trends (2001-2011) in the Incidence and Hospital Death Rates Associated with the In-Hospital Development of Cardiogenic Shock after Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2016; 9(2):117-25. PMC: 4794369. DOI: 10.1161/CIRCOUTCOMES.115.002359. View

Batsides G, Massaro J, Cheung A, Soltesz E, Ramzy D, Anderson M . Outcomes of Impella 5.0 in Cardiogenic Shock: A Systematic Review and Meta-analysis. Innovations (Phila). 2018; 13(4):254-260. DOI: 10.1097/IMI.0000000000000535. View

Harjola V, Lassus J, Sionis A, Kober L, Tarvasmaki T, Spinar J . Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015; 17(5):501-9. DOI: 10.1002/ejhf.260. View

ONeill W, Schreiber T, Wohns D, Rihal C, Naidu S, Civitello A . The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol. 2013; 27(1):1-11. PMC: 4238821. DOI: 10.1111/joic.12080. View

Ramzy D, Soltesz E, Anderson M . New Surgical Circulatory Support System Outcomes. ASAIO J. 2020; 66(7):746-752. PMC: 7316144. DOI: 10.1097/MAT.0000000000001194. View

Leurent G, Garlantezec R, Auffret V, Hacot J, Coudert I, Filippi E . Gender differences in presentation, management and inhospital outcome in patients with ST-segment elevation myocardial infarction: data from 5000 patients included in the ORBI prospective French regional registry. Arch Cardiovasc Dis. 2014; 107(5):291-8. DOI: 10.1016/j.acvd.2014.04.005. View

Rihal C, Naidu S, Givertz M, Szeto W, Burke J, Kapur N . 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino.... J Am Coll Cardiol. 2015; 65(19):2140-1. DOI: 10.1016/j.jacc.2015.02.043. View

Chair S, Yu D, Ng M, Wang Q, Cheng H, Wong E . Evolvement of left ventricular assist device: the implications on heart failure management. J Geriatr Cardiol. 2016; 13(5):425-30. PMC: 4984573. DOI: 10.11909/j.issn.1671-5411.2016.05.015. View

Bahrami H, Kronmal R, Bluemke D, Olson J, Shea S, Liu K . Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008; 168(19):2138-45. PMC: 3038918. DOI: 10.1001/archinte.168.19.2138. View

10.

Bernhardt A, Hakmi S, Sinning C, Lubos E, Reichenspurner H . A newly developed transaortic axial flow ventricular assist device: Early clinical experience. J Heart Lung Transplant. 2018; 38(4):466-467. DOI: 10.1016/j.healun.2018.09.022. View

11.

Kapur N, Whitehead E, Thayer K, Pahuja M . The science of safety: complications associated with the use of mechanical circulatory support in cardiogenic shock and best practices to maximize safety. F1000Res. 2020; 9. PMC: 7391013. DOI: 10.12688/f1000research.25518.1. View

12.

Lemaire A, Anderson M, Lee L, Scholz P, Prendergast T, Goodman A . The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2013; 97(1):133-8. DOI: 10.1016/j.athoracsur.2013.07.053. View

13.

Bertoglio L, Katsarou M, Scandroglio M, Bertoldi L, Chiesa R, Pappalardo F . Surgical transaxillary placement of the Impella 5.0 ventricular assist device. J Card Surg. 2019; 34(2):92-98. DOI: 10.1111/jocs.13978. View

14.

Mitchell O, Feldman D, Diakow M, Sigal S . The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016; 8:39-50. PMC: 4847598. DOI: 10.2147/HMER.S74612. View

15.

Thomas M, Blaine C, Dawnay A, Devonald M, Ftouh S, Laing C . The definition of acute kidney injury and its use in practice. Kidney Int. 2014; 87(1):62-73. DOI: 10.1038/ki.2014.328. View

16.

Moustafa A, Khan M, Saad M, Siddiqui S, Eltahawy E . Impella Support Versus Intra-Aortic Balloon Pump in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Meta-Analysis. Cardiovasc Revasc Med. 2021; 34:25-31. DOI: 10.1016/j.carrev.2021.01.028. View

17.

Potapov E, Schweiger M, Lehmkuhl E, Vierecke J, Stepanenko A, Weng G . Gender differences during mechanical circulatory support. ASAIO J. 2012; 58(4):320-5. DOI: 10.1097/MAT.0b013e318251cdf9. View

18.

Talbott E, Rager J, Brink L, Benson S, Bilonick R, Wu W . Trends in acute myocardial infarction hospitalization rates for US States in the CDC tracking network. PLoS One. 2013; 8(5):e64457. PMC: 3661496. DOI: 10.1371/journal.pone.0064457. View

19.

Henrion J . Hypoxic hepatitis. Liver Int. 2011; 32(7):1039-52. DOI: 10.1111/j.1478-3231.2011.02655.x. View

20.

Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A . Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. Resuscitation. 2012; 84(5):609-15. DOI: 10.1016/j.resuscitation.2012.10.001. View